Summit Therapeutics Shares Sink After FDA Doesn't Approve Lung Cancer Treatment
By Connor Hart
Shares of Summit Therapeutics fell after the Food and Drug Administration didn't approve the company's investigational treatment for certain types of lung cancer.
The stock dropped 18%, to $11.59, in premarket trading Monday. Through Friday's close, shares have lost about a fifth of their value year to date.
Summit Therapeutics on Sunday said it has received a complete response letter from the FDA regarding its biologics license application for ivonescimab in combination with platinum-containing chemotherapy, a treatment for patients with locally advanced or metastatic non-small cell lung cancer, who had already received certain therapies.
The FDA determined there was insufficient evidence that showed the combined treatment extended patients' lives.
"We are disappointed for patients and their families awaiting additional treatment options in this setting," said Robert Duggan, co-chief executive of Summit Therapeutics.
Ivonescimab was initially approved for marketing authorization in China in May 2024, where it was developed by Summit's Chinese partner Akeso. The therapy hasn't been approved by any regulatory authority in Summit's license territories, including the U.S. and Europe.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
November 16, 2026 06:53 ET (11:53 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular

5 Stocks to Buy After Earnings

7 Undervalued Stocks That Crushed Earnings

This Newly Undervalued Stock Has Plenty of Growth Ahead

Are These Riskier Bond ETFs Worth the Higher Yields?

